Navigation Links
Transgenomic Reports Fourth Quarter Financial Results

OMAHA, Neb., Feb. 24 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) today reported financial results for the three and 12 months ended December 31, 2009, and provided a business update.

Fourth Quarter Financial Results

Net income for the fourth quarter of 2009 was $129,000 or $0.00 per diluted share, compared with a net loss of $219,000 or $0.00 per share fo413) NET CASH FLOWS USED IN INVESTING ACTIVITIES (377) (399) EFFECT OF FOREIGN CURRENCY EXCHANGE RATE CHANGES ON CASH (19) (140) --- ---- NET CHANGE IN CASH AND CASH EQUIVALENTS 871 (952) CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 4,771 5,723 ----- ----- CASH AND CASH EQUIVALENTS AT END OF PERIOD $5,642 $4,771 ====== ======

                       Transgenomic, Inc.
                   Summary Financial Results
        Unaudited Condensed Consolidated Balance Sheets
                     (dollars in thousands)
                                      December 31,  December 31,
                                         2009          2008
                                       ---------     ---------
      Cash and cash equivalents          $5,642      $4,771
      Accounts receivable (net of
       allowances for bad debts of
       $310 and $388, respectively)       4,522       5,385
      Inventories (net of allowance
       for obsolescence of $507 and
       $108, respectively)                3,552       4,775
      Prepaid expenses and other
       current assets                       738         654
                                            ---         ---
          Total current assets           14,454      15,585
    PROPERTY AND EQUIPMENT, NET             967       1,198
      Other assets (net of
       accumulated amortization of
       $525 and $425, respectively)         583         773
                                            ---         ---
                                        $16,004     $17,556
                                        =======     =======
      Accounts payable                   $1,013        $905
      Other accrued expenses              2,517       2,810
      Accrued compensation                  573         520
          Total current liabilities       4,103       4,235
      Other long term liabilities           239         116
          Total liabilities               4,342       4,351
    STOCKHOLDERS' EQUITY                 11,662      13,205
                                         ------      ------
                                        $16,004     $17,556
                                        =======     =======

SOURCE Transgenomic, Inc.

Back to top

r the fourth quarter of 2008.

Net sales were $6.5 million during the fourth quarter 2009, compared with $6.1 million during the comparable period of 2008. Gross profit was $3.4 million or 52 percent of net sales during the fourth quarter of 2009, compared with gross profit of $3.4 million or 55 percent of net sales during the comparable period of 2008.  Operating expenses were $3.1 million during the fourth quarter of 2009, compared with $3.4 million during the same period of 2008.  The 2008 operating expenses included a goodwill impairment charge of $638,000 and income from foreign currency revaluation of $0.5 million.  Cash and cash equivalents were $5.6 million as of December 31, 2009, compared with $4.8 million as of December 31, 2008.

Full Year Financial Results

The Company reported a net loss for 2009 of $1.9 million or $0.04 per share, compared with a net loss for 2008 of $495,000 or $0.01 per share.

Net sales for 2009 were $22.0 million, compared with $24.0 million for 2008.  Gross profit was $11.6 million or 53 percent of net sales for 2009, compared with gross profit of $13.6 million or 57 percent of net sales for 2008.  Operating expenses were $13.5 million for 2009, which included expense from foreign currency revaluation of $0.3 million.  Operating expenses for 2008 were $14.0 million, which included a goodwill impairment of $638,000, income from foreign currency revaluation of $1.0 million and a restructuring charge of $118,000.  Cash flow from operations was $1.3 million for 2009, compared with cash flow used in operations of $413,000 for 2008.  

Comment and Outlook

Craig Tuttle, president and chief executive officer, commented, "We took a number of steps in the fourth quarter of 2009 that are expected to have a positive effect on the financial performance of Transgenomic for many years to come, as we added to and enhanced our platform technologies for use in drug discovery and in diagnostic screening.  The decision to execute the broad and exclusive license agreement with Dana-Farber Cancer Institute for Cold-PCR already is proving to be a wise one, as it gives us the ability to improve the sensitivity of a multitude of genetic tests while adding new ones to our product offerings.  For example, earlier this month we announced that in a study we conducted in conjunction with a major pharmaceutical company we validated Cold-PCR technology to detect colorectal tumor-associated K-RAS mutations with 100 percent concordance between Transgenomic's mutation results obtained in plasma and the matched tumor K-RAS genotypes. We will continue our validation studies throughout the year and develop additional cancer assays to complement our K-RAS kit for commercial use and for processing in both our CLIA-certified laboratory and pharmacogenomics laboratory as well as direct sales to end users.

"As personalized medicine continues to evolve, we are working with pharmaceutical companies and are in discussions with many more for the use of Cold-PCR to understand the mechanism of action of various drugs and the predictive value of a custom diagnostic assay. Cold-PCR has the potential to markedly improve patient care and earlier diagnosis of several diseases.

"We are assembling the building blocks that we believe ultimately will be a major force in the early diagnosis of Parkinson's disease. During the quarter we signed an exclusive licensing option with Gene Solutions for a set of validated mutations found in Parkinson's disease patients that can form the basis of a novel and accurate diagnostic test that will work with Transgenomic's mitochondrial mutation detection technology.  In addition, we completed the clinical validation in our CLIA lab of the NuroPro® Parkinson's disease test, fulfilling the terms of our licensing and collaboration agreement with Power3 Medical. We continue to be in full compliance with the license terms, maintaining our worldwide rights to this exclusive license."

Commenting on the sales of instruments, Mr. Tuttle went on to say, "As we had anticipated, the timing of several OEM instrument sales that shifted from the third quarter to the fourth led to significant revenue growth on a sequential quarter basis.  Our OEM sales were extremely strong in the fourth quarter and, as the economy improves, we hope to see continued strength here."

Conference Call

Company management will discuss fourth quarter and full year 2009 financial results and answer questions during a conference call today beginning at 5:00 p.m. Eastern time. To access the call via telephone, please dial 800-862-9098 or 785-424-1051.  The call also will be broadcast live over the Internet. To listen to the webcast, please log onto the Company's Investor Relations web page at and follow the instructions. An archived recording of the call can be accessed using the same link listed above for 14 days after the call. Investors can also listen to a replay via telephone until 11:59 p.m. Eastern time on Wednesday, March 10, 2010 by dialing 800-374-0328 or 402-220-0663.

About Transgenomic, Inc.  

Transgenomic, Inc. ( ) is a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis, providing products and services in DNA mutation detection and discovery for clinical research, clinical molecular diagnostics and pharmacogenomics analyses. Its product offerings include the WAVE® Systems and associated consumables specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. With broad applicability to genetic research, over 1,475 systems have been shipped to customers in more than 30 countries. The SURVEYOR® Mutation Detection Kits and SURVEYOR Check-It Kit provide reagents and protocols for high sensitivity detection of mutations in DNA. In addition, HANABI automated chromosome harvesting systems improve laboratory productivity with consistent quality compared with manual methods for cytogenetic analyses. Service offerings include the Transgenomic Molecular Laboratory, which provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases. Transgenomic Pharmacogenomics Services is a CRO for pharmacogenomic, translational research and clinical trials.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

                            Transgenomic, Inc.
                        Summary Financial Results
          Unaudited Condensed Consolidated Statements of Operations
                 (dollars in thousands except per share data)
                             Three Months Ended            Year Ended
                                 December 31,              December 31,
                             2009          2008        2009          2008
                             ----          ----        ----          ----
    NET SALES              $6,515         $6,126     $22,023       $23,993
    COST OF GOODS SOLD      3,127          2,776      10,418        10,345
                            -----          -----      ------        ------
        Gross profit        3,388          3,350      11,605        13,648
        Selling, general
         administrative     2,397          1,972      10,319        10,795
        Research and
         development          714            649       3,182         2,465
         charges                -            110           -           118
        Goodwill Impairment     -            638           -           638
                              ---            ---         ---           ---
                            3,111          3,369      13,501        14,016
                                                           -             -
     OPERATIONS               277            (19)     (1,896)         (368)
        Interest income         1             (5)         15            74
        Other, net              7             (3)          3            12
                                8             (8)         18            86
     INCOME TAXES             285            (27)     (1,878)         (282)
    INCOME TAX EXPENSE        156            192          42           213
                              ---            ---         ---           ---
    NET INCOME (LOSS)         129           (219)     (1,920)         (495)
                              ===           ====      ======          ====
        From continuing
         operations         $0.00          $0.00      $(0.04)       $(0.01)
     OUTSTANDING       49,189,672     49,189,672  49,189,672    49,189,672
     OUTSTANDING       49,217,942     49,189,672  49,189,672    49,189,672
                        Transgenomic, Inc.
                    Summary Financial Results
      Unaudited Condensed Consolidated Statements of Cash Flows
                      (dollars in thousands)
                                                    Year Ended
                                                    December 31,
                                                 2009         2008
                                                 ----         ----
     OPERATING ACTIVITIES                      $1,267        $(
SOURCE Transgenomic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR
2. Transgenomic, Inc. Executes License Option agreement for Parkinsons Disease Diagnostic Markers with Gene Solutions, LLC
3. Reminder Webcast Alert: Transgenomic, Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
4. Webcast Alert: Transgenomic Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
5. Transgenomic Signs Exclusive License for Cold-PCR Technology From the Dana-Farber Cancer Institute
6. Transgenomic and Power3 Medical Complete Agreement for Exclusive License of Neurodegenerative Biomarker Test
7. Transgenomic Establishes Collaboration With the National Cancer Institute to Investigate Mitochondrial Genome and Associated Nuclear Genes in Cancer Cell Lines
8. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
9. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results
10. Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009
11. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results
Post Your Comments:
(Date:10/9/2015)... DIEGO , Oct. 9, 2015 Ansun ... (Infectious Disease Society of America ) regarding the compassionate ... transplant patient on a respirator who was co-infected with ... a five-day course of therapy, O 2 requirement ... the patient was able to go off the respirator ...
(Date:10/8/2015)... October 9, 2015 ® ... diagnostic colonoscopy. The NOCT study also assessed the ... --> ® ) in adult patients ... study also assessed the compliance, safety, patient acceptability ... today announced positive top line results for its ...
(Date:10/8/2015)... PITTSBURGH , Oct. 8, 2015 /PRNewswire/ ... pharmaceutical company, will host a conference call and webcast ... ET to review the value to be created for ... TASE) through Mylan,s offer to acquire the company. During ... outlines the compelling proposition for Perrigo shareholders. Mylan,s offer ...
Breaking Medicine Technology:
... IDEV Technologies, Inc. (IDEV) today announced the firm ... Australia,s regulatory agency for medical drugs and devices, for ... and peripheral procedures. "We are pleased to ... SUPERA VERITAS in the Australian market later this year," ...
... 28, 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ... evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the ... Paris, France. "The data we are ... an important new treatment option for patients with multiple ...
Cached Medicine Technology:
(Date:10/9/2015)... ... 09, 2015 , ... A new health tool that helps identify if a ... ( ) – just in time for the cold and flu season, which ... for many in the U.S., the real start of cold/flu season is the start ...
(Date:10/9/2015)... ... October 09, 2015 , ... Dentist in Huntington Beach ... system that uses clear, plastic aligners. This alternative to braces has become wildly ... allow patients to complete treatment in privacy. Additionally, Invisalign aligners are removable, so ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... The Asthma ... the US Centers for Disease Control and Prevention (CDC) to improve the knowledge and ... that AAFA has been awarded a project by the CDC and allows AAFA to ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... individuals from all walks of life to save money on the high cost ... $25 per month per medication, individuals and families can receive their medications delivered ...
(Date:10/9/2015)... ... October 09, 2015 , ... Ryan Fox, ... largest recreational dispensaries in Colorado, says the latest figures on the state’s sales ... maturing into a legitimate industry. , Last month, according to the ...
Breaking Medicine News(10 mins):
... ... Integration project team including Drummond Group Inc., the trusted interoperability test lab, to conduct a ... project and leading the testing efforts with strong support from the project stakeholders. ... Austin, TX (PRWEB) December 7, ...
... ... medical research. , ... AZ (PRWEB) December 7, 2009 -- is doing its part to help find a ... Cure Catheters to its list of nearly 45,000 products., , ,Cure Medical is a forward-thinking ...
... , NEW ORLEANS, Dec. 7 ... Ruth Pettengell, M.D. of St. George,s Hospital, University of London during ... Meeting updated results from the pivotal phase III EXTEND (PIX 301) ... or refractory, aggressive non-Hodgkin,s lymphoma ("NHL") patients who have failed ...
... , OAK BROOK, Ill., Dec. ... academic medical center (AMC) members for their achievements in ... 10 organizations are noted for modeling best practices in ... ) , The winners were determined using 2008 ...
... the loss of a key segment of DNA can lead to ... this kind of genetic alteration can cause obesity. The results are ... Dr Sadaf Farooqi from the University of Cambridge and Dr Matt ... with severe obesity. The team scanned each child,s entire genome ...
... Dec. 6 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... 003-A1 study, known as the 003 trial, demonstrating that carfilzomib ... patients. These data were presented today at the ASH/ASCO Joint ... of Hematology (ASH) in New Orleans. Enrollment in this trial ...
Cached Medicine News:
Hydragel K20 is Sebia's quality line of manual agarose gel electrophoresis products. Samples are applied utilizing the same patented applicator combs that is used for sample application on the HYDRAS...
Eliminating the need for any manual pipetting, the HydraPLUS delivers precise micro-volumes of sample directly from primary tubes to four HYDRASYS sample applicators contained in a built-in humidity ...
Handheld Digital Retinal Camera...
Medicine Products: